IPP Bureau
CORONA Remedies receives EU-GMP certification for hormone facility
By IPP Bureau - June 02, 2026
Accreditations for Bhayla manufacturing site strengthen the company’s global quality credentials and support expansion of its hormone portfolio into regulated international markets
Marksans Pharma to acquire Netherlands-based QliniQ
By IPP Bureau - June 02, 2026
Acquisition provides direct access to the Dutch healthcare market, enhancing Marksans’ sales, distribution and market-access capabilities across regulated European markets
FDA okays AstraZeneca’s bladder cancer drug Imfinzi Plus BCG
By IPP Bureau - June 02, 2026
First immunotherapy combination approved in the US for BCG-naïve high-risk NMIBC demonstrates a 32% reduction in the risk of disease recurrence, progression, or death
Scientists develop rapid nanosensor to detect gut health biomarker for IBD and diabetes
By IPP Bureau - June 02, 2026
Novel fluorescent nanosensor enables real-time detection of indole-3-propionic acid (IPA), paving the way for faster gut health screening, point-of-care diagnostics, and wearable monitoring devices
Moderna and Merck’s mRNA cancer vax combo shows 5-year survival in melanoma trial
By IPP Bureau - June 02, 2026
An exploratory overall survival signal also leaned in favor of the combination, though the companies noted the result remains preliminary
CellCarta and Leica Biosystems expand push to streamline precision medicine development
By IPP Bureau - June 02, 2026
The collaboration introduces a flexible, end-to-end CDx framework designed to adapt to shifting regulatory environments
BioNTech and Bristol Myers Squibb drug shows strong early signal in lung cancer trial
By IPP Bureau - June 02, 2026
The safety profile was described as manageable, though not without notable toxicities
Eli Lilly drug slashes lung cancer recurrence risk by 83% in landmark phase 3 trial
By IPP Bureau - June 02, 2026
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
Ebola vax on the anvil?
By IPP Bureau - June 02, 2026
CEPI will commit up to US $50 million to fund preclinical research and Phase 1 clinical trials of Moderna’s mRNA-based vaccine candidate
Hyderabad gets new 'Oval' fertility hub
By IPP Bureau - June 02, 2026
Fertility platform launches flagship clinic with advanced IVF tech
Yoginii partners with Panacea Biotec to expand wellness portfolio
By IPP Bureau - June 02, 2026
Collaboration brings Staart Prime, ChilRun and NikoMom products to Yoginii’s platform, strengthening its family-focused wellness ecosystem and supporting women through motherhood and family care
M|O|C Cancer Care’s research gains global recognition at ASCO 2026
By IPP Bureau - June 02, 2026
The accepted studies span several critical areas of oncology, including nutrition, genomics, precision medicine, patient-reported outcomes, and community-based cancer care
Bristol Myers Squibb wins EU approval for Opdivo-based frontline treatment in advanced hodgkin lymphoma
By IPP Bureau - June 02, 2026
The approval is supported by results from the Phase 3 SWOG 1826 trial
STRIDE-based regimens show survival momentum in EMERALD-3 liver cancer trial
By IPP Bureau - June 02, 2026
While overall survival data remain immature, the results pointed to a favourable trend.
Aragen completes commercial-scale GMP manufacturing of Daretabart in 9 months
By IPP Bureau - June 02, 2026
Anti-GD2 monoclonal antibody for high-risk neuroblastoma advances toward BLA submission following successful tech transfer from California to Bengaluru
